Consultancy firms told to step up as bosses threaten to cut ties Advisory Stretched corporates are under pressure and looking to slash costs – and consultancy firms are in the firing line, writes Maria Ward-Brennan. The golden age of post-pandemic consulting is fading, leaving traditional advisory firms with a clear ultimatum: innovate or be replaced. The next generation of executives is pushing to reduce dependence on external consultants. [...]
LivaNova to Announce Third-Quarter 2026 Results Business Wire LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. [...]
OCP Announces Date of Second Quarter and First Half 2026 Earnings Business Wire OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. [...]
KPMG wields axe again with 200 tech and cyber roles on the block September 15, 2026 KPMG UK is set to lay off hundreds of staff in its data and tech division in the latest round of redundancies at the Big Four firm. The new round of cuts will affect 200 roles from its advisory business, according to the Financial Times, and amounts to about 4 per cent of the firm’s [...]
The common sense deficit hitting the City’s professional services firms September 2, 2026 The rise of AI has put serious pressure on professional services firms to figure out hiring and training strategies as an industry built to sell knowledge faces a knowledge gap as a new era enters the workforce with skills very different from the cohort ahead of them, writes Maria Ward-Brennan. Much of the conversation about [...]
Former Interpath Advisory chair takes helm at sustainability consultancy after chief executive exit September 1, 2026 Interpath Advisory’s former chair will lead the City-headquartered, sustainability-focused consultancy Anthesis Group as its new chair, as its chief executive steps down. Tamara Box, previously City law firm Reed Smith‘s managing partner for Europe and the Middle East, is set to take on the new chair of Anthesis Group’s board of directors this week after [...]
Affluent Big Four partners lack ‘fire in the belly’ to disrupt consulting market August 27, 2026 The trend of Big Four partners leaving to launch boutique consultancies has accelerated in recent years. But Q5 co-founder has told City AM that many will struggle to build true challenger brands without an “all or nothing” approach. Five founders, including managing partner Olly Purnell, launched boutique consultancy firm Q5 at the height of the global financial [...]
Argan, Inc. to Announce Second Quarter Fiscal 2027 Results and Host Conference Call on Wednesday, September 2, 2026 August 19, 2026 Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its second quarter fiscal 2027 financial results after the market closes on Wednesday, September 2, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Wednesday, September 2, 2026 at 5:00 p.m. ET. Participants can [...]
Private equity-backed advisory firm acquires specialist music boutique August 14, 2026 Mid-tier accountancy and advisory firm BKL has snapped up a smaller counterpart in its latest acquisition, aiming to strengthen its focus on the music, media, and entertainment sector in London. City-based BKL, which offers tax, accounting, and business advisory services, has snapped up specialist music accountancy firm Dales Evans, as it “continues to expand its [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET